September 29, 2014: Concortis Biosystems will be an exhibitor at the World ADC Summit to be held in San Diego October 26-29, 2014. We will present our new product line Safe & Easy Toxin™ and new services.
SAN DIEGO, June 25, 2014 /PRNewswire/ -- Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Press Release
At Concortis, we interface complex synthetic chemistry with antibody research providing our clients with the latest technologies and comprehensive services to advance ADC projects from discovery to IND. Our ADC platform encompasses:
- ADC screening tools
- Bioactive molecules (toxins) for research and as cGMP grade
- Optimized linker-toxins
- Conjugation services
- ADC toxicity screening
- Homogenous conjugation methodologies
- ADC optimization & processing
Concortis has developed multiple proprietary technology platforms to transform biologics such as antibodies, proteins, and peptides into therapeutics that are more efficient and have fewer side effects than traditional treatments.
Concortis' platforms include next generation antibody drug conjugate (ADC), tumor-targeted drug delivery, and next generation payloads. We use versatile linkers, functionalized carriers proteins, biocompatible polymers, and highly potent small molecule toxins in the execution of our platforms. These mechanisms combined with our proprietary conjugation chemistries distinguish our technologies from traditional methods.